Product Overview

Novonorm 0.5 mg is a prescription oral antidiabetic medication manufactured by Novo Nordisk India. It belongs to the class of meglitinides and is specifically indicated for the treatment of type 2 diabetes mellitus. The product is supplied in a strip containing 15 tablets, each strength 0.5 mg of repaglinide. Pack sizes available include 60, 90, and 120 tablets, allowing patients to select the most convenient option for long‑term therapy. This medication is intended for use alongside diet and exercise to improve blood glucose control in adults with type 2 diabetes who require additional glycemic management beyond metformin or other oral agents.

What is Novonorm

Repaglinide, the active ingredient in Novonorm, acts by stimulating the pancreatic beta‑cells to release insulin in a glucose‑dependent manner. Unlike sulfonylureas, it does not increase insulin secretion at low glucose concentrations, which reduces the risk of prolonged hypoglycemia. The drug is rapidly absorbed, reaches peak plasma concentrations within one hour, and is eliminated primarily through hepatic metabolism. Its short duration of action makes it ideal for controlling post‑prandial glucose spikes when taken just before meals. The medication is marketed under the brand name Novonorm and is formulated as immediate‑release tablets that dissolve quickly in the gastrointestinal tract.

Uses and Benefits

The primary use of Novonorm is to lower elevated blood glucose levels in patients with type 2 diabetes who have not achieved adequate control with lifestyle modification alone. Clinical studies have demonstrated that repaglinide reduces HbA1c by approximately 0.5% to 1.0% when used as monotherapy or in combination with metformin or sulfonylureas. In addition to improving glycemic control, patients often experience modest weight stability and a lower incidence of edema compared with some other oral agents. The rapid onset and short half‑life allow flexible dosing around meals, providing clinicians with a tool to tailor therapy to individual meal patterns and glucose monitoring.

How It Works

Repaglinide binds to ATP‑sensitive potassium channels on the surface of pancreatic beta‑cells, triggering calcium influx and subsequent insulin release only when blood glucose concentrations rise above a threshold. Because the drug’s effect is tightly coupled to glucose levels, it minimizes insulin secretion during fasting periods, thereby lowering the probability of nocturnal hypoglycemia. Additionally, repaglinide has been shown to reduce hepatic glucose production, contributing to overall post‑prandial glucose suppression. These pharmacodynamic properties are documented in peer‑reviewed literature, including entries on PubMed and the U.S. Food and Drug Administration.

Dosage Guidelines

Patients are advised to take Novonorm 0.5 mg tablet orally approximately 30 minutes before the main meals of the day. The initial dose is usually 0.5 mg before breakfast and dinner; based on the patient’s response and tolerability, the dose may be titrated up to a maximum of 4 mg per day, divided into multiple administrations before each main meal. Dose adjustments are recommended for individuals with renal impairment, elderly patients, or those with hepatic dysfunction. It is essential that the prescribing clinician monitors blood glucose regularly and modifies the dose accordingly. The medication should never be taken between meals or after a meal, as its glucose‑dependent action would be ineffective. For detailed dosing algorithms, refer to the National Institutes of Health guideline on type 2 diabetes management.

Side Effects

Like all pharmaceutical agents, Novonorm can be associated with adverse effects. The most frequently reported side effects include hypoglycemia, especially when combined with other glucose‑lowering drugs, weight gain, and gastrointestinal discomfort such as nausea or abdominal pain. Less common but clinically significant reactions comprise hepatic enzyme elevations, skin rash, and rare instances of hypersensitivity. Patients should be instructed to recognize the signs of low blood sugar—such as sweating, tremors, confusion, or palpitations—and to treat them promptly with fast‑acting carbohydrates. If severe hypoglycemia occurs, medical attention should be sought immediately. For an exhaustive list of side effects, consult the Drugs.com database.

Warnings and Precautions

Novonorm is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment (eGFR <30 mL/min/1.73 m²). Caution is advised in individuals with a history of hepatic disease, as the drug is metabolized primarily in the liver. Concomitant use with certain antibiotics, such as clarithromycin, may increase repaglinide plasma levels and necessitate dose reduction. Pregnant or breastfeeding women should only use the medication under the supervision of a qualified healthcare professional. Regular monitoring of renal function and liver enzymes is recommended during long‑term therapy. Additional safety information can be found on the U.S. Food and Drug Administration prescribing information page.

FAQs

1. How should I store Novonorm tablets? Store the medication at room temperature away from moisture and heat. Keep the strip tightly closed and out of reach of children. Do not refrigerate unless instructed by your pharmacist. Proper storage maintains the integrity of the active ingredient and ensures consistent dosing.
2. Can Novonorm be taken with other diabetes medications? Yes, it is often prescribed together with metformin or insulin, but only under medical supervision. Combining therapies can enhance glucose control, yet it also increases the risk of hypoglycemia. Your healthcare provider will adjust doses and monitor blood glucose closely to achieve safe and effective results.
3. What should I do if I miss a dose? If you forget to take a dose before a meal, skip it and resume your regular schedule with the next meal. Do not double the dose to make up for the missed one. Taking extra medication can cause an unexpected drop in blood sugar and lead to adverse effects.
4. Is Novonorm safe for elderly patients? Clinical studies indicate that older adults may be more sensitive to the hypoglycemic effects of repaglinide. Dose reduction is recommended for patients with reduced kidney function or other comorbidities. Close monitoring by a physician is essential to avoid serious low‑blood‑sugar episodes and to tailor therapy to the individual’s overall health status.
5. Where can I find more information about repaglinide? Comprehensive details are available from reputable sources such as the MedlinePlus website, the Wikipedia entry, and the official product labeling from Novo Nordisk. These resources provide insight into mechanism of action, clinical trial results, and patient counseling tips.

Related Products

• Okamet 500 Mg (Metformin)
• Novofine 31G Needle (Device)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)
• Glycomet-GP 1 Forte (Metformin/Glimepiride)
• Glimepiride 4 mg (Generic)